| 中文名称: | SN50 | ||||
|---|---|---|---|---|---|
| 英文名称: | SN50 | ||||
| 别名: | Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro | ||||
| CAS No: | 213546-53-3 | 分子式: | C129H230N36O29S | 分子量: | 2781.5 |
| CAS No: | 213546-53-3 | ||||
| 分子式: | C129H230N36O29S | ||||
| 分子量: | 2781.5 | ||||
基本信息
|
产品编号： |
S11216 |
||||
|
产品名称： |
SN50 |
||||
|
CAS: |
213546-53-3 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
2781.50 |
-20℃ |
1个月 |
||
|
化学名： |
Ala-Ala-Val-Ala-Leu-Leu-Pro-Ala-Val-Leu-Leu-Ala-Leu-Leu-Ala-Pro-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
100mg/mL (35.95mM) |
|||
|
Ethanol |
100mg/mL (35.95mM) |
||||
|
Water |
100mg/mL (35.95mM) |
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
0.3595mL |
1.7976mL |
3.5952mL |
|
5mM |
0.0719mL |
0.3595mL |
0.7190mL |
|
10mM |
0.0360mL |
0.1798mL |
0.3595mL |
生物活性
|
产品描述 |
一种可渗透细胞的NF-κB易位抑制剂。 |
|
靶点 |
NF-κB |
|
体外研究 |
Pretreatment with SN50 results in a significant reduction in amount of PI-positive cells at 12,24,and 48h time-point post TBI compared with vehicle-treated groups.Topical SN50 suppresses nuclear factor-κB activation in local cells and reduces the incidence of epithelial defects/ulceration in healing corneas.Myofibroblast generation,macrophage invasion,activity of matrix metalloproteinases,basement membrane destruction,and expression of cytokines are all decreased in treated corneas compared with controls.Treating the human gastric cancer cells SGC7901 with SN50 could significantly enhance the effects of LY294002 on inducing cell death after 24h.SN50 can inhibit translocation of NF-kB and production of inflammatory cytokines that are implicated in lipopolysaccharide (LPS)-induced lung injury. |
|
体内研究 |
Treatment with SN50 accelerates the recovery of motor functional outcome from 1st to 4th day.Animals subjected to SN50 pretreatment demonstrate a significant decrease in the visuospatial learning latencies relative to the control group at 7 and 8 days post-TBI.Pretreatment with SN50 results in a significant reduction of NF-κB p65 protein levels from 6 to 48 h post-TBI and TNF-a protein levels from 12 to 48h post-TBI. |
推荐实验方法(仅供参考)
|
细胞实验: |
|
|
SN50 is diluted in distilled sterilization water to create a stock solution.The final concentration of the SN50 solution used is 18µM.Cell viability is assessed with MTT assay.To determine the effects of SN50 on enhancing the role of LY294002 on SGC7901 cells,cells are plated into 96-well microplates (7×1000 cells/well) and cultured for 24h.Then LY294002 (50µM),SN50 (18µM) and LY294002+SN50 are added to the culture medium and cell viability is assessed with MTT 24h after drug treatment. |
|
|
动物实验: |
|
|
Mice:SN50 is prepared in saline (total volume:1μL,concentration:0.1μg/μL).SN50 is administered into the ipsilateral cerebral ventricle 10 min before TBI.After TBI,the bone flap is replaced,the scalp incision is sutured,and then mice are allowed to awaken and returned to their cages.Mice are killed at 1,6,12,24,48,and 72h after operation.Loss of plasmalemma integrity is evaluated by intraperitoneal injection of PI 1h before killing the animal. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
